Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

News

Allergan and Pfizer terminate merger agreement

6 April 2016 | By Victoria White

The decision was driven by the actions announced by the US Department of Treasury to reform inversion tax rules, which the companies concluded qualified as an “Adverse Tax Law Change”. Market rumour suggests that Pfizer will now target Shire or AstraZeneca and shares in both companies went up with the…

First glimpse of an immature HIV-neutralising antibody

6 April 2016 | By Victoria White

Scientists have described the first-ever immature antibody found in a powerful class of immune molecules effective against HIV. TSRI biologist Jiang Zhu called the antibody a “teenager” and said it gives scientists a unique view of the steps needed to prompt the immune system to effectively target HIV...